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Background
Inactivated SIV vaccines provide potent protection against
challenge by SIV in the macaque model. Following evi-
dence that host cell antigens can confer protection, and
evidence that this protection can be conveyed to naive
macaques in serum transfer experiments, we now show
that this protection is due to immunity against HLA class
II proteins. Recently it was shown that humans immu-
nised with inactivated virus made an antibody response
against HLA class I and II antigens expressed on the sur-
face of the cell line used to grow the virus. Importantly,
immunised individuals did not break tolerance to self-
antigens. Here we show protection via different epitopes
on the HLA class II protein in xeno-immunised macaques
that may provide a correlate of protection.
Methods
Macaques vaccinated with fixed inactivated human T cells
(C8166) or murine L cells expressing DR4 were chal-
lenged with SIV propagated in a human T cell line to
assess the breadth of protection. Macaque sera were
assayed for antibodies reacting with human MHC class II
proteins using a luminex assay. Antibody neutralisation
data was determined by TZM-bl single round SIV infectiv-
ity assay.
Results
Animals immunised with either C8166 cells or L cells
expressing DR4 produced an antibody response that cross
reacted with all human MHC class II proteins tested.
Those animals that had a high anti class II antibody titre
were protected against SIV challenge, and correlated with
an ability to neutralise SHIV-W61D grown in C8166 cells
in vivo.
Conclusion
We have previously published data that shows allo-immu-
nisation in humans by whole inactivated virus generates
an allo-specific response. Xeno-immunisation of
macaques generates a pan specific anti-HLA class II
response indicating that anti-framework or conserved
regions are immunogenic, and induce a protective immu-
nity. These results suggest that allo-immunisation of
macaques is a more appropriate model for evaluating
allo-immunisation of humans as an HIV/AIDS vaccine
strategy.
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